Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171470 · ClinicalTrials.gov registry record · Phase 3
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
A Phase 3 study of Dyspepsia, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00171470 is a Phase 3 study of Dyspepsia that has completed, run by Novartis. The registered enrollment target is 60 participants, below the 71-participant average among 11 other Dyspepsia trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00171470, a Phase 3 study of Dyspepsia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.
Conditions Studied
Interventions
- DRUG Tegaserod
Study Locations (1)
New Jersey
- http://www.novartisclinicaltrials.com/etrials/DiseaseID21/Dyspepsia-clinical-trials.go - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171470
The ClinicalTrials.gov registry entry for NCT00171470 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 11 other Dyspepsia trials with a reported enrollment target (15% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyspepsia appearing as the primary indexed condition, and to 1 intervention - of which Tegaserod is the first listed.
NCT00171470 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00171470 about?
NCT00171470 is a clinical study titled "The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.". Study to provide initial data to assess the safety and efficacy of tegaserod use in patients with dyspepsia that are being treated with proton pump inhibitors (PPI's) for heartburn.
What is the current status of trial NCT00171470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2005-04. Estimated completion is 2006-08.
What conditions does trial NCT00171470 study?
This clinical trial studies the following conditions: Dyspepsia.
What interventions are being tested in trial NCT00171470?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00171470?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171470 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyspepsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Visible Abdominal Distension
RECRUITING · NA
-
Zypan Functional Dyspepsia
RECRUITING · NA
-
High Resolution Gastric Mapping and Gastroduodenal Manometry
RECRUITING · NA
-
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
RECRUITING · NA
-
Famotidine and Antacids for Treatment of Dyspepsia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.